A self-driven, microfluidic, integrated-circuit biosensing chip for detecting four cardiovascular disease biomarkers

• DOI: 10.1016/j.bios.2023.115931
• Publication Date: 2023-12-12T18:33:16Z
• Authors: Pei-Rong Li; Sasi Kiran Boilla; Chih-Hung Wang; Pei-Chien Lin; Chien-Nan Kuo; Tsung-Heng Tsai; Gwo-Bin Lee
• Keywords: C-Reactive Protein; Cardiovascular Diseases; Microfluidics; Natriuretic Peptide, Brain; Humans; Fibrinogen; Biosensing Techniques; Biomarkers; Peptide Fragments

Cardiovascular diseases (CVDs) claimed the lives of nearly 21 million people worldwide in 2021, accounting for 30% of global deaths. However, one in five CVD patients is unaware that they have the disease, emphasizing the need for accurate biomarker monitoring. Herein we developed an integrated microfluidic system (IMS) for rapid quantification of four CVD biomarkers, including N-terminal pro B-type natriuretic peptide (NT-proBNP), fibrinogen, cardiac troponin I (cTnI), and C-reactive protein (CRP)- via aptamer-coated interdigitated electrodes (IDE) with integrated circuits (IC) and a self-driven IMS for sample treatment. The device was composed of plasma filtration, metering, and fluidic delay modules, and the former could extract 45% of plasma from a 20-μL blood sample; the metering module could quantify 5 μL of plasma within 90 s. Subsequently, the plasma was transported to a detection chamber, where IC-based IDE sensors made measurements within 5 min. The entire 15-min process allowed us to evaluate biomarkers across a wide dynamic range: NT-proBNP (0.1-10,000 pg/mL), fibrinogen (50-1,000 mg/dL), cTnI (0.1-10,000 pg/mL), and CRP (0.5-9 mg/L). Given that spiked blood samples were measured with reasonable accuracy (>80%), the IMS could see utility in CVD risk assessment and personalized medicine.